

FORM PTO-1449 U.S. Department of Commerce
Patent and Trademark Office

Attorney Docket Number
5470-368

Serial No.
10/511,989

LIST OF DOCUMENTS CITED BY APPLICANT

(Use several sheets if necessary)

Applicants: Jenny Ting et al..

Filing Date: May 25, 2005

Group: 1633

U. S. PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate
	1.	6,432,442	08-13-2002	Bertin, et al.	435	7.92	
prev. rvwd.	2.	2001/0029033	10-11-2001	Sham et al.	435	69.1	
	3.	2003/0027757	02-06-2003	Bertin et al.	514	12	

FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Subclass	Translation Yes No

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

/SDP/	4.	Accession Number AF389420, <i>Homo sapiens</i> NOD27 (NOD27) mRNA, complete cds; Source: <i>Homo sapiens</i> (June 4, 2001)					
	5.	Accession No. AF231021; <i>Homo sapiens</i> Leucine-Rich-Repeat Protein RNO2 mRNA, complete cds; Source: <i>Homo sapiens</i> ; (2001)					
	6.	Accession No. NM_033297; <i>Homo sapiens</i> Neuronal Apoptosis Inhibitor Protein 12 (NALP12), mRNA; Source: <i>Homo sapiens</i> (2003)					
	7.	Accession Number AF526389; <i>Homo sapiens</i> cryopyrin (CIAS1) gene, intron 6; Source: <i>Homo sapiens</i> (July 2, 2002)					
	8.	Accession Number AK025131; <i>Homo sapiens</i> cDNA: FLJ21478 fis, clone COL05012; Source: <i>homo sapiens</i> (August 29, 2000)					
	9.	Accession Number AK025212; <i>Homo sapiens</i> cDNA: FLJ21559 fis, clone COL06406; Source: <i>Homo sapiens</i>					
	10.	Accession Number AK025362; <i>Homo sapiens</i> cDNA: FLJ21709 fis, clone COL10077; Source: <i>Homo sapiens</i> (August 29, 2000)					
	11.	Accession Number AK027416; <i>Homo sapiens</i> cDNA FLJ14510 fis, clone NT2RM1000623, weakly similar to RIBONUCLEASE INHIBITOR; Source: <i>Homo sapiens</i> (May 10, 2001)					
	12.	Accession Number AK074109; <i>Homo sapiens</i> mRNA for FLJ00180 protein; Source: <i>Homo sapiens</i> (January 21, 2002)					
↓	13.	Accession Number AK074133; <i>Homo sapiens</i> mRNA for FLJ00206 protein, Source: <i>Homo sapiens</i> (January 21, 2002)					
/SDP/	14.	Accession Number AK074182; <i>Homo sapiens</i> mRNA for FLJ00255 protein, Source: <i>Homo sapiens</i> (January 21, 2002)					

EXAMINER
*EXAMINER

DATE CONSIDERED

Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 U.S. Department of Commerce Patent and Trademark Office		Attorney Docket Number 5470-368	Serial No. 10/511,989
LIST OF DOCUMENTS CITED BY APPLICANT (Use several sheets if necessary)		Applicants: Jenny Ting et al..	
		Filing Date: May 25, 2005	Group: 1633
/SDP/	15.	Accession Number AK090431; <i>Homo sapiens</i> mRNA for FLJ00348 protein; Source: <i>Homo sapiens</i> (July 4, 2002)	
	16.	Accession Number AK090439; <i>Homo sapiens</i> mRNA for FLJ00359 protein; Source: <i>Homo sapiens</i> (July 4, 2002)	
	17.	Accession Number AK090476; <i>Homo sapiens</i> mRNA for FLJ00398 protein; Source: <i>Homo sapiens</i> (July 4, 2002)	
	18.	Accession Number AK097030; <i>Homo sapiens</i> cDNA FLJ39711 fis, clone SMINT2013032; Source: <i>Homo sapiens</i> (July 4, 2002)	
	19.	Accession Number AY051112; <i>Homo sapiens</i> cryopyrin (CIAS1) gene, exon 1; Source: <i>Homo sapiens</i> (August 15, 2001)	
	20.	Accession Number AY051113; <i>Homo sapiens</i> cryopyrin (CIAS1) gene, exon 2; Source: <i>Homo sapiens</i> (August 15, 2001)	
	21.	Accession Number AY051114; <i>Homo sapiens</i> cryopyrin (CIAS1) gene, exon 3; Source: <i>Homo sapiens</i> (August 15, 2001)	
	22.	Accession Number AY051115; <i>Homo sapiens</i> cryopyrin (CIAS1) gene, exon 5; Source: <i>Homo sapiens</i> (August 15, 2001)	
	23.	Accession Number AY051116; <i>Homo sapiens</i> cryopyrin (CIAS1) gene, exons 7 and 8; Source: <i>Homo sapiens</i> (August 15, 2001)	
	24.	Accession Number AY051117; <i>Homo sapiens</i> cryopyrin (CIAS1) gene, exon 9 and complete cds, alternatively spliced; Source: <i>Homo sapiens</i> (August 15, 2001)	
	25.	Accession Number AY056059; <i>Homo sapiens</i> cryopyrin (CIAS1) gene, exon 4; Source: <i>Homo sapiens</i> (August 15, 2001)	
	26.	Accession Number AY056060; <i>Homo sapiens</i> cryopyrin (CIAS1) gene, exon 6; Source: <i>Homo sapiens</i> (August 15, 2001)	
	27.	Accession Number AY092033; <i>Homo sapiens</i> NALP3 intermediate isoform (NALP3) mRNA, complete cds; Source: <i>Homo sapiens</i> (March 27, 2002)	
	28.	Accession Number AY116204; <i>Homo sapiens</i> monarch-1 mRNA, complete cds; alternatively spliced; Source: <i>Homo sapiens</i> (May 29, 2002)	
	29.	Accession Number AY116205; Accession Number AY116207; <i>Homo sapiens</i> monarch-1 splice form II mRNA, complete cds; alternatively spliced; Source: <i>Homo Sapiens</i> (May 29, 2002)	
	30.	Accession Number AY116206; <i>Homo sapiens</i> monarch-1 splice form III mRNA, complete cds; alternatively spliced; Source: <i>Homo Sapiens</i> (May 29, 2002)	
	31.	Accession Number AY116207; <i>Homo sapiens</i> monarch-1 splice form IV mRNA, complete cds; alternatively spliced; Source: <i>Homo Sapiens</i> (May 29, 2002)	
↓	32.	Accession Number AY154469; <i>Homo sapiens</i> NALP14 (NALP14) mRNA, complete cds; Source: <i>Homo sapiens</i> (September 25, 2002)	
/SDP/	33.	Accession Number BC013199; <i>Homo sapiens</i> NOD9 protein, mRNA (cDNA clone IMAGE: 4387619),	

EXAMINER
*EXAMINER

DATE CONSIDERED

Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 U.S. Department of Commerce Patent and Trademark Office LIST OF DOCUMENTS CITED BY APPLICANT (Use several sheets if necessary)		Attorney Docket Number 5470-368	Serial No. 10/511,989
		Applicants: Jenny Ting et al..	
		Filing Date: May 25, 2005	Group: 1633
		partial cds; Source: <i>Homo sapiens</i> (August 27, 2001)	
/SDP/	34.	Accession Number NM_004895 <i>Homo sapiens</i> cold auto inflammatory syndrome 1 (CIAS1), transcript variant 1, mRNA; Source: <i>Homo sapiens</i> (2004)	
↓	35.	Accession Number NM_024618; <i>Homo sapiens</i> NOD9 protein (NOD9), transcript variant 1, mRNA; Source: <i>Homo sapiens</i> (2003)	
↓	36.	Accession Number NM_145827; <i>Mus musculus</i> cold auto inflammatory syndrome 1 homolog (human) (Cias1), mRNA; Source: <i>Mus musculus</i> (2003)	
/SDP/	37.	Accession Number NM_170722; <i>Homo sapiens</i> NOD9 protein (NOD9), transcript variant 2, mRNA; Source: <i>Homo sapiens</i> (2003)	
↙	38.	Accession Number NT_009325; <i>Homo sapiens</i> chromosome 11 genomic contig; Source: <i>Homo sapiens</i> (2003)	
↙	39.	Accession Number NT_009334; <i>Homo sapiens</i> chromosome 11 working draft sequence segment; Source: <i>Homo sapiens</i> (August 23, 2001)	
↙	40.	Accession Number NT_015360; <i>Homo sapiens</i> chromosome 16 working draft sequence segment; Source: <i>Homo sapiens</i> (February 6, 2002)	
↙	41.	Accession Number NT_024766; <i>Homo sapiens</i> chromosome 16 working draft sequence segment; Source: <i>Homo sapiens</i> (February 6, 2002)	
prev. rvwd	42.	Aganna, et al. 2002. Association of mutations in the NALP3/CIAS1/PYPAF1 gene with a broad phenotype including recurrent fever, cold sensitivity, sensorineural deafness, and AA amyloidosis. <i>Arthritis Rheum</i> 46:2445.	
↙	43.	Akira, et al. 2001. Toll-like receptors: critical proteins linking innate and acquired immunity. <i>Nat Immunol</i> 2:675.	
↙	44.	Alexopoulos, et al. 2001. Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. <i>Nature</i> 413:732.	
↙	45.	Banerjee, et al. 2001. The leucine-rich repeat domain can determine effective interaction between RPS2 and other host factors in arabidopsis RPS2-mediated disease resistance. <i>Genetics</i> 158:439.	
/SDP/	46.	Beg, et al. 1993. Tumor necrosis factor and interleukin-1 lead to phosphorylation and loss of I kappa B alpha: a mechanism for NF-kappa B activation. <i>Mol Cell Biol</i> 13:3301.	
prev. rvwd	47.	Bertin and DiStefano. 2000. The PYRIN domain: a novel motif found in apoptosis and inflammation proteins. <i>Cell Death Differ.</i> 7:1273.	
/SDP/	48.	Bertin, et al. 1999. Human CARD4 protein is a novel CED-4/Apaf-1 cell death family member that activates NF-kappaB. <i>J Biol Chem</i> 274:12955.	
↓	49.	Beutler, B. 2001. Autoimmunity and apoptosis: the Crohn's connection. <i>Immunity</i> 15:5.	
↓	50.	Bouchier-Hayes, et al. 2001. CARDINAL, a novel caspase recruitment domain protein, is an inhibitor of multiple NF-kappa B activation pathways. <i>J Biol Chem</i> 276:44069.	
/SDP/	51.	Brown, et al. 1998. The MHC class II transactivator (CIITA) requires conserved leucine charged domains for interactions with the conserved W box promoter element. <i>Nucleic Acids Res.</i> 26:4128.	

EXAMINER

*EXAMINER

DATE CONSIDERED

Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 U.S. Department of Commerce Patent and Trademark Office		Attorney Docket Number 5470-368	Serial No. 10/511,989
LIST OF DOCUMENTS CITED BY APPLICANT (Use several sheets if necessary)		Applicants: Jenny Ting et al..	
		Filing Date: May 25, 2005	Group: 1633
prev. rvwd	52.	Buchanan and Gay. 1996. Structural and functional diversity in the leucine-rich repeat family of proteins. <i>Prog Biophys Mol Biol.</i> 65:1.	
	53.	Chen and Goeddel. 2002. TNF-R1 signaling: a beautiful pathway. <i>Science</i> 296:1634	
/SDP/	54.	Cressman, et al. 1999. A defect in the nuclear translocation of CIITA causes a form of type II bare lymphocyte syndrome. <i>Immunity</i> . 10:163.	
/SDP/	55.	Dangl and Jones. 2001. Plant pathogens and integrated defence responses to infection. <i>Nature</i> 411:826.	
prev. rvwd	56.	Dodds, et al. 2001. Six Amino Acid Changes Confined to the Leucine-Rich Repeat beta-Strand/beta-Turn Motif Determine the Difference between the 1 and 12 Rust Resistance Specificities in Flax. <i>Plant Cell</i> 13:163.	
/SDP/	57.	Dode, et al. 2002. New Mutations of CIAS1 That Are Responsible for Muckle-Wells Syndrome and Familial Cold Urticaria: A Novel Mutation Underlies Both Syndromes. <i>Am J Hum Genet</i> 70:1498.	
↓	58.	Dowds, et al. 2003. Regulation of cryopyrin/Pypaf1 signaling by pyrin, the familial Mediterranean fever gene product. <i>Biochem. Biophys. Res. Commun.</i> 302(3):575-80.	
↓	59.	Feldmann, et al. 2002. Chronic infantile neurological cutaneous and articular syndrome is caused by mutations in CIAS1, a gene highly expressed in polymorphonuclear cells and chondrocytes. <i>Am J Hum Genet</i> 71:198.	
↓	60.	Fiorentino, et al. 2002. A novel PAAD-containing protein that modulates NF-kappa B induction by cytokines tumor necrosis factor-alpha and interleukin-1beta. <i>J Biol Chem</i> 277:35333.	
/SDP/	61.	Fontes, et al. 1999. Interactions between the class II transactivator and CREB binding protein increase transcription of major histocompatibility complex class II genes. <i>Mol. Cell Biol.</i> 19:941.	
/SDP/	62.	Fukui et al. "Haematopoietic Cell-Specific CDM Family Protein DOCK2 is Essential for Lymphocyte Migration" <i>Nature</i> 412: 826-831 (2001)	
/SDP/	63.	Hake, et al. 2000. CIITA leucine-rich repeats control nuclear localization, In vivo recruitment to the major histocompatibility complex (MHC) class II enhanceosome, and MHC class II gene transactivation [In Process Citation]. <i>Mol. Cell. Biol</i> 20(20):7716-25.	
↓	64.	Harton and Ting. 2000. Class II transactivator: mastering the art of major histocompatibility complex expression. <i>Mol. Cell Biol</i> 20(17):6185-94.	
↓	65.	Harton, et al. 1999. GTP binding by class II transactivator: role in nuclear import. <i>Science</i> 285:1402.	
/SDP/	66.	Harton, et al. 2002. Leucine-rich repeats of the class II transactivator control its rate of nuclear accumulation. <i>Hum Immunol.</i> 63(7):588-601	
prev. rvwd	67.	Heery, et al. 1997. A signature motif in transcriptional co-activators mediates binding to nuclear receptors. <i>Nature</i> 387:133.	
/SDP/	68.	Hemmi, et al. 2000. A Toll-like receptor recognizes bacterial DNA. <i>Nature</i> 408:740.	
↓	69.	Hlaing, et al. 2001. Molecular cloning and characterization of DEFCAP-L and -S, two isoforms of a novel member of the mammalian Ced-4 family of apoptosis proteins. <i>J. Biol. Chem.</i> 276(12):9230-8.	
/SDP/	70.	Hoffman, et al. 2001. Mutation of a new gene encoding a putative pyrin-like protein causes familial cold autoinflammatory syndrome and Muckle-Wells syndrome. <i>Nat. Genet.</i> 29:301.	

EXAMINER
*EXAMINER

DATE CONSIDERED

Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 U.S. Department of Commerce Patent and Trademark Office LIST OF DOCUMENTS CITED BY APPLICANT (Use several sheets if necessary)		Attorney Docket Number 5470-368	Serial No. 10/511,989
		Applicants: Jenny Ting et al..	
		Filing Date: May 25, 2005	Group: 1633
/SDP/	71.	Holt, et al. 2003. Resistance gene signaling in plants - complex similarities to animal innate immunity. <i>Curr Opin Immunol</i> 15:20.	
	72.	Hugot, et al. 2001. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. <i>Nature</i> 411:599.	
	73.	Inohara, et al. 1999. Nod1, an Apaf-1-like activator of caspase-9 and nuclear factor- kappaB. <i>Journal of Biological Chemistry</i> 274:14560.	
	74.	Inohara, et al. 2000. An induced proximity model for NF-kappa B activation in the Nod1/RICK and RIP signaling pathways. <i>J Biol Chem</i> 275:27823.	
	75.	Inohara, et al. 2001. Human nod1 confers responsiveness to bacterial lipopolysaccharides. <i>J.Biol.Chem.</i> 276(4):2551-4.	
	76.	International Search Report for International Patent Application No. PCT/US03/13562 mailed on October 1, 2004	
	77.	Kaisho and Akira. 2000. Critical roles of Toll-like receptors in host defense. <i>Crit Rev Immunol</i> 20:393.	
	78.	Koonin and Aravind. 2000. The NACHT family - a new group of predicted NTPases implicated in apoptosis and MHC transcription activation. <i>Trends.Biochem.Sci.</i> 25(5):223-4.	
↓	79.	Kretsovali, et al. 1998. Involvement of CREB binding protein in expression of major histocompatibility complex class II genes via interaction with the class II transactivator. <i>Mol.Cell Biol.</i> 18:6777.	
/SDP/	80.	Kretsovali, et al. 2001. Self-association of CIITA correlates with its intracellular localization and transactivation. <i>J.Biol.Chem.</i> 276(34):32191-7.	
	81.	Li and Verma. 2002. NF-kappaB regulation in the immune system. <i>Nat Rev Immunol</i> 2:125.	
	82.	Linhoff, et al. 2001. Two distinct domains within CIITA mediate self-association: involvement of the GTP binding and leucine-rich repeat domains. <i>Mol.Cell Biol</i> 21(9):3001-11.	
/SDP/	83.	MacKeigan, et al. 2000. MEK inhibition enhances paclitaxel-induced tumor apoptosis. <i>J Biol Chem</i> 275:38953.	
	84.	Manji, et al. 2002. PYPAF1, a PYRIN-containing Apaf1-like protein that assembles with ASC and regulates activation of NF-kappa B. <i>J Biol Chem</i> 277:11570.	
	85.	Martinon, et al. 2002. The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-beta. <i>Mol Cell</i> 10:417.	
	86.	Masternak, et al. 2000. CIITA is a transcriptional coactivator that is recruited to MHC class II promoters by multiple synergistic interactions with an enhanceosome complex. <i>Genes and Development</i> 14:1156.	
	87.	Miceli-Richard, et al. 2001. CARD15 mutations in Blau syndrome. <i>Nat Genet</i> 29:19.	
	88.	Nelson, L. M. 2001. Autoimmune ovarian failure: comparing the mouse model and the human disease. <i>J Soc Gynecol Investig</i> 8:S55.	
↓	89.	Nickerson, et al. 2001. Dendritic cell-specific MHC class II transactivator contains a caspase recruitment domain that confers potent transactivation activity. <i>J Biol Chem</i> 276:19089.	
/SDP/	90.	Ogura, et al. 2001. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. <i>Nature</i> 411(6837):603-606.	

prev. rvwd

 EXAMINER
 *EXAMINER

DATE CONSIDERED

Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 U.S. Department of Commerce Patent and Trademark Office LIST OF DOCUMENTS CITED BY APPLICANT (Use several sheets if necessary)		Attorney Docket Number 5470-368	Serial No. 10/511,989
		Applicants: Jenny Ting et al..	
		Filing Date: May 25, 2005	Group: 1633
/SDP/	91.	Ogura, et al. 2001. Nod2, a Nod1/Apaf-1 family member that is restricted to monocytes and activates NF-kappaB. <i>J Biol Chem</i> 276:4812.	
	92.	Pan, et al. 2000. Divergent evolution of plant NBS-LRR resistance gene homologues in dicot and cereal genomes. <i>J Mol Evol</i> 50:203.	
	93.	Phillips et al. "Expression of RNO-2 Inhibits Growth and Induces Differentiation and Apoptosis in leukemia Cells" <i>Blood</i> 98(11): 192b (2001) (Abstract)	
	94.	Poltorak, et al. 1998. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. <i>Science</i> 282:2085-2088.	
↓	95.	Reith and Mach. 2001. The bare lymphocyte syndrome and the regulation of MHC expression. <i>Annu Rev Immunol</i> 19:331	
/SDP/	96.	Riley, et al. 1995. Activation of class II MHC genes requires both the X box region and the class II transactivator (CIITA). <i>Immunity</i> 2:533.	
prev. rvwd	97.	Samuels, et al. 1998. Familial Mediterranean fever at the millennium. Clinical spectrum, ancient mutations, and a survey of 100 American referrals to the National Institutes of Health. <i>Medicine (Baltimore)</i> 77:268.	
/SDP/	98.	Schuster and Nelson. 2000. Toll receptors: an expanding role in our understanding of human disease. <i>J.Leukoc.Biol.</i> 67(6):767-73.	
/SDP/	99.	Schwandner, et al. 1999. Peptidoglycan- and lipoteichoic acid-induced cell activation is mediated by toll-like receptor 2. <i>J Biol Chem</i> 274:17406.	
/SDP/	100.	Shami et al. "Identification and Characterization of a Novel Gene that is Upregulated in Leukaemia Cells by Nitric Oxide" <i>British Journal of Haematology</i> 112(1): 138-147 (2001)	
duplicate	101.	Shami, et al. 2001. Identification and characterization of a novel gene that is upregulated in leukaemia cells by nitric oxide. <i>Br J Haematol</i> 112:138	
/SDP/	102.	Sisk, et al. 2000. MHC class II transactivator inhibits IL-4 gene transcription by competing with NF-AT to bind the coactivator CREB binding protein (CBP)/p300. <i>J.Immunol.</i> 165(5):2511-7.	
↓	103.	Sisk, et al. 2001. Self-association of CIITA and its transactivation potential. <i>Mol Cell Biol</i> 21:4919.	
	104.	Spilianakis, et al. 2000. Acetylation by PCAF enhances CIITA nuclear accumulation and transactivation of major histocompatibility complex class II genes. <i>Mol.Cell.Biol.</i> 20(22):8489-98.	
↓	105.	Srinivasula et al. "The PYRIN-CARD Protein ASC is an Activating Adaptor for Capase-1" <i>The Journal of Biological Chemistry</i> 277(24): 21119-21122 (2002)	
/SDP/	106.	Stehlik, et al. 2002. The PAAD/PYRIN-family protein ASC is a dual regulator of a conserved step in nuclear factor kappaB activation pathways. <i>J Exp Med</i> 196:1605.	
prev. rvwd	107.	Steimle, et al. 1993. Complementation cloning of an MHC class II transactivator mutated in hereditary MHC class II deficiency (or bare lymphocyte syndrome). <i>Cell</i> 75:133.	
/SDP/	108.	Suzuki, et al. 2002. IRAK-4 as the central TIR signaling mediator in innate immunity. <i>Trends Immunol</i> 23:50.	
/SDP/	109.	Tong, et al. 2000. Mater encodes a maternal protein in mice with a leucine-rich repeat domain homologous to porcine ribonuclease inhibitor. <i>Mamm Genome</i> 11:281.	

 EXAMINER
 *EXAMINER

DATE CONSIDERED

Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 U.S. Department of Commerce Patent and Trademark Office		Attorney Docket Number 5470-368	Serial No. 10/511,989
LIST OF DOCUMENTS CITED BY APPLICANT (Use several sheets if necessary)		Applicants: Jenny Ting et al.	
		Filing Date: May 25, 2005	Group: 1633
↑ duplicates	107.	Steinle, et al. 1993. Complementation cloning of an MHC class II transactivator mutated in hereditary MHC class II deficiency (or bare lymphocyte syndrome). <i>Cell</i> 75:135.	
	108.	Suzuki, et al. 2002. IRAK-4 as the central TNF signaling mediator in innate immunity. <i>Trends Immunol</i> 23:50.	
	109.	Tong, et al. 2000. Mater encodes a maternal protein in mice with a leucine-rich repeat domain homologous to porcine ribonuclease inhibitor. <i>Mamm Genome</i> 11:281.	
↓ /SDP/	110.	Tong, et al. 2000. Mater, a maternal effect gene required for early embryonic development in mice. <i>Nat Genet</i> 26:267.	
	111.	Torchia, et al. 1997. The transcriptional co-activator p/CIP binds CBP and mediates nuclear-receptor function. <i>Nature</i> 387:677.	
	112.	Towey and Kelly. 2002. Nuclear localisation of CIITA is controlled by a carboxy terminal leucine-rich repeat region. <i>Mol Immunol</i> 38:627.	
	113.	Traut, T. W. 1994. The functions and consensus motifs of nine types of peptide segments that form different types of nucleotide-binding sites. <i>Eur J Biochem</i> 222:9.	
	114.	Tschopp et al. "NALPS: A Novel Protein Family Involved in Inflammation" <i>Nature Reviews</i> 4(2): 95-104 (2003)	
	115.	Van Der Hoorn, et al. 2001. Identification of distinct specificity determinants in resistance protein cf-4 allows construction of a cf-9 mutant that confers recognition of avirulence protein avr4. <i>Plant Cell</i> 13:273.	
	116.	Wang, et al. 2002. PYPAF7, a novel PYRIN-containing Apaf1-like protein that regulates activation of NF-kappa B and caspase-1-dependent cytokine processing. <i>J. Biol. Chem.</i> 277(33):29874-80	
	117.	Williams et al. "Cutting Edge: Monarch-1: A Pyrin/Nucleotide-Binding Domain/Leucine-Rich Repeat Protein that Controls Classical and nonclassical MHC Class I Genes" <i>The Journal of Immunology</i> 170: 5354-5358 (2003)	
	118.	Wong, et al. 2002. Regulation and specificity of MHC2TA promoter usage in human primary T lymphocytes and cell line. <i>J Immunol</i> 169:3112.	
	119.	Yao and Cooper. 1995. Requirement for phosphatidylinositol-3 kinase in the prevention of apoptosis by nerve growth factor. <i>Science</i> 267:2003.	
	120.	Zhang, et al. 1999. Bacterial lipopolysaccharide activates nuclear factor-kappaB through interleukin-1 signaling mediators in cultured human dermal endothelial cells and mononuclear phagocytes. <i>J Biol Chem</i> 274:7611.	
↓	121.	Zhou and Glimcher. 1995. Human MHC class II gene transcription directed by the carboxyl terminus of CIITA, one of the defective genes in type II MHC combined immune deficiency. <i>Immunity</i> . 2:545.	
/SDP/	122.	Zhu, et al. 2000. Transcriptional scaffold: CIITA interacts with NF-Y, RFX, and CREB to cause stereospecific regulation of the class II major histocompatibility complex promoter. <i>Mol. Cell Biol</i> 20(16):6051-61.	

EXAMINER
*EXAMINER

/Scott D. Priebe/

DATE CONSIDERED

10/12/2007

Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.